Mikhail Blagosklonny, MD, PhD (Misha) @Blagosklonny

TJKCB

TJKCB
宁静纯我心 感得事物人 写朴实清新. 闲书闲话养闲心,闲笔闲写记闲人;人生无虞懂珍惜，以沫相濡字字真。
首页 文章页 文章列表 博文目录
给我悄悄话
打印 被阅读次数
I am pleased to join Oncotarget as an Editor-in-Chief this June, 2024.

This is a great journal that was started in 2010. The journal has published impactful research over the years by leaders in the field. The journal is indexed in PubMed, PMC, and MEDLINE and has its own digital archive. Oncotarget follows the guidelines based on the recommendations of the Committee on Publication Ethics (COPE). The journal conducts author interviews and promotes published research through press releases.

https://lnkd.in/e3pnxfQr

https://lnkd.in/eJ63zVeM

https://lnkd.in/e7PeqzKF

https://lnkd.in/eFyTKPGK

I’d like to invite my colleagues to submit manuscripts and would particularly encourage translational research, progress in precision oncology, therapy for cancer’s hallmarks, drug resistance, plasticity, epigenetics, microbiome, environmental carcinogenesis, intersection of behavior and biology of cancer, cancer immunotherapy, functional precision medicine, molecular imaging, theranostics, stem cells, liquid biopsy and tumor heterogeneity.

Problems such as CNS primary or metastatic cancers, blood brain barrier research, viruses and cancer, cell cycle and cell death, biomarkers (predictive, prognostic, and pharmacodynamic), pro-drugs, nanotherapeutics, drug metabolism, novel omics, tumor dormancy and early detection are of interest.

Technology enabling of progress using AI, statistics and novel clinical trial designs, new devices for diagnostics and therapeutics, single cell profiling, 3-D visualization of TME, single molecule visualization are relevant areas of interest.

We welcome clinical case reports, case series, commentaries, reviews, clinical trial results, and Meeting Reports.

Please feel free to reach out to me directly if you have any questions or manuscripts we might consider.

I hope you will have a positive experience in sharing your contributions of new knowledge and/or expertise in an efficient manner with Oncotarget.

I look forward to having positive impact in this new role working with Mikhail Blagosklonny, MD, PhD (Misha) @Blagosklonny and Andrei Gudkov, PhD at Roswell Park Comprehensive Cancer Center

I previously served as the founding Editor-in-Chief of Cancer Biology and Therapy for 18 years from 2001-2019.

https://lnkd.in/e94AgCBk

https://lnkd.in/epRJ4N77

The Warren Alpert Medical School of Brown University Brown University @BrownUCancer WIN Consortium in cancer personalized medicine hashtagLegorretaCancerCenter hashtageldeirylab American Cancer Society American Cancer Society Cancer Action Network (ACS CAN) OncoAlert OncoDaily AACI (Association of American Cancer Institutes) National Cancer Institute (NCI) The National Institutes of Health National Academy of Inventors The Cancer Letter
 
 
 
 
Shengwen Calvin Li, PhD,EIC,FRSB,FRSM
 


 
Add a comment…
 

View Khalid El Bairi’s profile • 2nd

Working for global oncology and research integrity. Fascinated by ovarian cancer and biomarkers. Columnist for @ASCO | #LINO23 Alumnus | 2023 African Cancer Leaders Institute Fellow | ASCO IDEA 2024 Awardee
A lot of research integrity concerns in this journal as well!
 
 
7 Replies on Khalid El Bairi’s comment

View Wafik S. El-Deiry, MD, PhD, FACP’s profile (He/Him)Author

Associate Dean for Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, RI
Khalid El Bairi this is from at least 6 years ago while the journal was competing with other top journals. I believe the journal was maliciously targeted at the time and has put this behind them. It is fully listed at present after fighting back. I said to communicate current concerns.
 
 
 
 
 

View Khalid El Bairi’s profile • 2nd

Working for global oncology and research integrity. Fascinated by ovarian cancer and biomarkers. Columnist for @ASCO | #LINO23 Alumnus | 2023 African Cancer Leaders Institute Fellow | ASCO IDEA 2024 Awardee
Does Oncotarget waives the APCs for authors from LMICs ? Thanks
 
 
 
 
 
 
 

View Anupam Agarwal, MD, MPH’s profile • 2nd

Senior Biotech Executive| Cardiac safety| Gene Therapy| AI| Angel Investor
Congratulations on joining Oncotarget as the Editor-in-Chief, Dr. El-Deiry! I wish you great success in this new role and look forward to the valuable contributions you and your team will bring to the field.
 
 
 
 
 

View Miguel Bronchud’s profile • 2nd

Co-Founder & Advisory Board at Regenerative Medicine Solutions
Congratulations Wafik. Good & traditionally independent scientific medical journal. Your experienced opinion and expertise will no doubt help it to become even better.
 
 
 
 
 

View John Tarantino’s profile • 2nd

Senior Counsel Adler Pollock & Sheehan PC & CEO IYLON Precision Oncology LLC TEDx Speaker Motivational Speaker Leadership Speaker Legal Ethics Speaker Philanthropy Speaker Community Engagement Speaker
Congratulations
 
 
 
 
 
登录后才可评论.